Chiltern Announces Early Phase Partnership With Tayside Academic Health Sciences Center

June 2, 2010

Company News Release

Chiltern International Limited (Chiltern), a global contract research organization, announced its latest collaboration with Tayside Academic Health Sciences Center (TAHSC), a joint venture between UK’s NHS Tayside and the University of Dundee. In this collaboration, Chiltern will partner with TAHSC to conduct and support Proof of Concept and Translational Medicine studies.

Chiltern will draw upon many parts of TAHSC, including the Clinical Research Center (CRC) which is located on the same University Medical School and hospital campus as Chiltern Early Phase and NHS Tayside’s Clinical Imaging and Interventional Center (CIIC). The CRC is the hub for clinical trial activity with links to additional satellite units in Tayside. Chiltern and the CRC will focus on Proof of Concept studies in areas such as diabetes, COPD, cardiovascular disease, neurological conditions and Hepatitis C.

The CIIC houses a 3T MRI scanner and a PET/CT scanner. A unique feature of the suite is an operating room situated between the MRI and PET/CT scanners, allowing ready access to these important tools before, during and after surgery. Ease of access to state of the art diagnostic equipment and expertise, the availability of Key Opinion Leaders in many disease areas as well as access to study subjects interested and available to participate in these studies, make this an ideal setting for performance and delivery of the highest caliber.

Glenn Kerkof, Chiltern CEO, stated, “We are proud of this new collaboration and confident that the world class Key Opinion Leaders in TAHSC will augment our expertise in our early phase business.”

Jill Belch, Professor, Tayside Research and Development Director, commented, “Supporting the local research community and building strong working relationships with industrial partners are key objectives for TAHSC. This agreement will allow potential access to new drugs for our patients in Tayside and allow our researchers to participate in a larger range of clinical studies.”

Related Content:

News